Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($1.10), $0.05 better than the analyst estimate of ($1.15). Revenue for the quarter came in at $19.7 million versus the consensus estimate of $20.29 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.